Literature DB >> 31013254

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Jithendra Kini Bailur1, Samuel S McCachren1,2, Deon B Doxie1, Mahesh Shrestha1, Katherine Pendleton1, Ajay K Nooka1,3, Natalia Neparidze4, Terri L Parker4, Noffar Bar4, Jonathan L Kaufman1,3, Craig C Hofmeister1,3, Lawrence H Boise1,3, Sagar Lonial1,3, Melissa L Kemp2, Kavita M Dhodapkar3,5, Madhav V Dhodapkar1,3.   

Abstract

Preneoplastic lesions carry many of the antigenic targets found in cancer cells but often exhibit prolonged dormancy. Understanding how the host response to premalignancy is maintained and altered during malignant transformation is needed to prevent cancer. In order to understand the immune microenvironment in precursor monoclonal gammopathy of undetermined significance (MGUS) and myeloma, we analyzed bone marrow immune cells from 12 healthy donors and 26 MGUS/myeloma patients by mass cytometry and concurrently profiled transcriptomes of 42,606 single immune cells from these bone marrows. Compared to age-matched healthy donors, memory T cells from both MGUS and myeloma patients exhibit greater terminal-effector differentiation. However, memory T cells in MGUS show greater enrichment of stem-like TCF1/7hi cells. Clusters of T cells with stem-like and tissue-residence genes were also found to be enriched in MGUS by single-cell transcriptome analysis. Early changes in both NK and myeloid cells were also observed in MGUS. Enrichment of stem-like T cells correlated with a distinct genomic profile of myeloid cells and levels of Dickkopf-1 in bone-marrow plasma. These data describe the landscape of changes in both innate and adaptive immunity in premalignancy and suggest that attrition of the bone-marrow-resident T cell compartment due to loss of stem-like cells may underlie loss of immune surveillance in myeloma.

Entities:  

Keywords:  Adaptive immunity; Cancer; Immunology; Oncology

Year:  2019        PMID: 31013254      PMCID: PMC6629164          DOI: 10.1172/jci.insight.127807

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  35 in total

1.  A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics.

Authors:  Faris Q B Alenzi; Stephen B Marley; John L Lewis; Anil Chandrashekran; Anthony N Warrens; John M Goldman; Myrtle Y Gordon
Journal:  Exp Hematol       Date:  2002-12       Impact factor: 3.084

2.  T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Kara Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

3.  Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.

Authors:  Kimberly Noonan; William Matsui; Paolo Serafini; Rebecca Carbley; Gladys Tan; Jahan Khalili; Mark Bonyhadi; Hyam Levitsky; Katie Whartenby; Ivan Borrello
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

4.  Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

Authors:  Yuhuan Zheng; Zhen Cai; Siqing Wang; Xiang Zhang; Jianfei Qian; Sungyoul Hong; Haiyan Li; Michael Wang; Jing Yang; Qing Yi
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

5.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Authors:  Erming Tian; Fenghuang Zhan; Ronald Walker; Erik Rasmussen; Yupo Ma; Bart Barlogie; John D Shaughnessy
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

6.  Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.

Authors:  Radek Spisek; Anjli Kukreja; Lin-Chi Chen; Phillip Matthews; Amitabha Mazumder; David Vesole; Sundar Jagannath; Henry A Zebroski; Andrew J G Simpson; Gerd Ritter; Brian Durie; John Crowley; John D Shaughnessy; Matthew J Scanlan; Ali O Gure; Bart Barlogie; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307

7.  Enhancement of clonogenicity of human multiple myeloma by dendritic cells.

Authors:  Anjli Kukreja; Aisha Hutchinson; Kavita Dhodapkar; Amitabha Mazumder; David Vesole; Revathi Angitapalli; Sundar Jagannath; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2006-07-31       Impact factor: 14.307

8.  Spatial reconstruction of single-cell gene expression data.

Authors:  Rahul Satija; Jeffrey A Farrell; David Gennert; Alexander F Schier; Aviv Regev
Journal:  Nat Biotechnol       Date:  2015-04-13       Impact factor: 54.908

9.  Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Keren Osman; Matthew D Geller
Journal:  J Exp Med       Date:  2003-11-24       Impact factor: 14.307

10.  Serial exome analysis of disease progression in premalignant gammopathies.

Authors:  S Zhao; M Choi; C Heuck; S Mane; B Barlogie; R P Lifton; M V Dhodapkar
Journal:  Leukemia       Date:  2014-02-05       Impact factor: 12.883

View more
  49 in total

1.  Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.

Authors:  Noffar Bar; Federica Costa; Rituparna Das; Alyssa Duffy; Mehmet Samur; Samuel McCachren; Scott N Gettinger; Natalia Neparidze; Terri L Parker; Jithendra Kini Bailur; Katherine Pendleton; Richa Bajpai; Lin Zhang; Mina L Xu; Tara Anderson; Nicola Giuliani; Ajay Nooka; Hearn J Cho; Aparna Raval; Mala Shanmugam; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  JCI Insight       Date:  2020-06-18

Review 2.  Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity.

Authors:  Athanasios Papadas; Garrett Arauz; Alexander Cicala; Joshua Wiesner; Fotis Asimakopoulos
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

3.  It takes T to tango: immunotherapy in MM.

Authors:  Vikas A Gupta; Madhav V Dhodapkar
Journal:  Blood       Date:  2022-03-03       Impact factor: 22.113

Review 4.  Aging-associated immune system changes in multiple myeloma: The dark side of the moon.

Authors:  Alissa Visram; Taxiarchis V Kourelis
Journal:  Cancer Treat Res Commun       Date:  2021-11-20

5.  Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients.

Authors:  Slavica Vuckovic; Christian E Bryant; Ka Hei Aleks Lau; Shihong Yang; James Favaloro; Helen M McGuire; Georgina Clark; Barbara Fazekas de St Groth; Felix Marsh-Wakefield; Najah Nassif; Edward Abadir; Vinay Vanguru; Derek McCulloch; Christina Brown; Stephen Larsen; Scott Dunkley; Liane Khoo; John Gibson; Richard Boyle; Douglas Joshua; P Joy Ho
Journal:  Blood Adv       Date:  2020-10-13

Review 6.  Immunotherapy of multiple myeloma.

Authors:  Simone A Minnie; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

7.  The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.

Authors:  Shih-Feng Cho; Liang Lin; Lijie Xing; Yuyin Li; Kenneth Wen; Tengteng Yu; Phillip A Hsieh; Nikhil Munshi; Joachim Wahl; Katja Matthes; Matthias Friedrich; Tara Arvedson; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Blood Adv       Date:  2020-09-08

Review 8.  How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.

Authors:  Adam D Cohen; Noopur Raje; Jessica A Fowler; Khalid Mezzi; Emma C Scott; Madhav V Dhodapkar
Journal:  Clin Cancer Res       Date:  2019-10-31       Impact factor: 12.531

Review 9.  Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Alan Howard; David Avigan; Manisha Bhutani; Adam D Cohen; Luciano J Costa; Madhav V Dhodapkar; Francesca Gay; Nicole Gormley; Damian J Green; Jens Hillengass; Neha Korde; Zihai Li; Sham Mailankody; Paola Neri; Samir Parekh; Marcelo C Pasquini; Noemi Puig; G David Roodman; Mehmet Kemal Samur; Nina Shah; Urvi A Shah; Qian Shi; Andrew Spencer; Vera J Suman; Saad Z Usmani; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2020-06-24       Impact factor: 5.742

10.  Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.

Authors:  Sagar Lonial; Susanna Jacobus; Rafael Fonseca; Matthias Weiss; Shaji Kumar; Robert Z Orlowski; Jonathan L Kaufman; Abdulraheem M Yacoub; Francis K Buadi; Timothy O'Brien; Jeffrey V Matous; Daniel M Anderson; Robert V Emmons; Anuj Mahindra; Lynne I Wagner; Madhav V Dhodapkar; S Vincent Rajkumar
Journal:  J Clin Oncol       Date:  2019-10-25       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.